Founded in 2017 in Schwyz, Liom (formerly Spiden) is building a wearable that measures glucose non-invasively using a miniaturised Raman spectroscopy platform. The technology achieves 12× higher light throughput than lab-scale devices, enabling smartwatch-sized hardware with more than 24-hour battery life. Liom has already demonstrated calibration-free glucose measurement on over 130 subjects and plans to launch its first commercial product in 2028. The company positions its device as a breakthrough over existing continuous glucose monitors that rely on microneedles, targeting mass-market adoption among consumers and athletes. Recent progress shifts the firm from pure R&D toward product development and commercialisation, supported by new board member and investor Marc Maurer, former co-CEO of On Running. To date, Liom has raised €67.6 million in venture funding, giving it resources to scale manufacturing and prepare for regulatory and market entry.

Total raised

$49M

Funding rounds

3

Latest round

Series A

Latest activity

Dec 2025